Aurinia Pharmaceuticals Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $283.1M | $235.1M | $175.5M | $134.0M | $45.6M | $50.1M | $318.0K | $463.0K |
| Cost of Revenue | $32.7M | $28.2M | $14.1M | $5.7M | $1.1M | $0 | $0 | — |
| Gross Profit | $250.4M | $206.9M | $161.4M | $128.4M | $44.5M | $50.1M | $318.0K | — |
| Gross Margin | 88.5% | 88.0% | 91.9% | 95.8% | 97.6% | 100.0% | 100.0% | — |
| Operating Expenses | ||||||||
| Research & Development | $32.5M | $20.8M | $49.6M | $45.0M | $51.1M | $50.3M | $52.9M | $41.4M |
| SG&A Expense | $101.8M | $172.0M | $195.0M | $196.4M | $173.5M | $97.3M | $22.3M | $13.7M |
| Operating Income | $104.9M | $-4.7M | $-91.7M | $-111.5M | $-180.7M | $-104.3M | $-90.9M | $-55.2M |
| Operating Margin | 37.1% | -2.0% | -52.2% | -83.2% | -396.3% | -208.1% | -28,598.4% | -11,930.9% |
| Interest Expense | — | — | $2.8M | $0 | $0 | — | $39.0K | $0 |
| Pretax Income | $114.2M | $7.4M | $-77.5M | $-106.4M | $-180.2M | $-102.8M | $-88.2M | $-53.0M |
| Income Tax Expense | $-173.0M | $1.7M | $551.0K | $1.8M | $760.0K | $-94.0K | $144.0K | $73.0K |
| Net Income | $287.2M | $5.8M | $-78.0M | $-108.2M | $-181.0M | $-102.7M | $-88.4M | $-53.1M |
| Net Margin | 101.5% | 2.4% | -44.5% | -80.7% | -396.8% | -204.9% | -27,794.0% | -11,464.1% |
| EPS (Basic) | $2.14 | $0.04 | $-0.54 | $-0.76 | $-1.40 | $-0.87 | $-0.95 | $-0.63 |
| EPS (Diluted) | $2.07 | $0.04 | $-0.54 | $-0.76 | $-1.40 | $-0.87 | $-0.95 | $-0.63 |
| Shares Outstanding (Basic) | 134.4M | 143.1M | 143.2M | 141.9M | 129.4M | 118.5M | 111.8M | 85.5M |
| Shares Outstanding (Diluted) | 138.7M | 146.2M | 143.2M | 141.9M | 129.4M | 118.5M | 111.8M | 85.5M |
| Dividends Per Share | — | — | — | — | — | — | — | — |